BEAM Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -677.47% compared to Beam Therapeutics's net margin of --. Beam Therapeutics's return on equity of -16.62% beat Perspective Therapeutics's return on equity of --.

Beam Therapeutics has a consensus price target of --, signalling upside risk potential of 69.42%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Beam Therapeutics, analysts believe Perspective Therapeutics is more attractive than Beam Therapeutics.

Beam Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $14.3M, which are larger than Perspective Therapeutics quarterly revenues of --. Beam Therapeutics's net income of -$96.7M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 6.80x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -677.47% compared to Beam Therapeutics's net margin of 10.05%. Beam Therapeutics's return on equity of -16.62% beat Electromed's return on equity of 15.62%.

Beam Therapeutics has a consensus price target of --, signalling upside risk potential of 69.42%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 19.01%. Given that Beam Therapeutics has higher upside potential than Electromed, analysts believe Beam Therapeutics is more attractive than Electromed.

Beam Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $14.3M, which are smaller than Electromed quarterly revenues of $14.7M. Beam Therapeutics's net income of -$96.7M is lower than Electromed's net income of $1.5M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 38.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 6.80x versus 4.33x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -677.47% compared to Beam Therapeutics's net margin of -10.5%. Beam Therapeutics's return on equity of -16.62% beat Myomo's return on equity of -84.04%.

Beam Therapeutics has a consensus price target of --, signalling upside risk potential of 69.42%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 25.27%. Given that Beam Therapeutics has higher upside potential than Myomo, analysts believe Beam Therapeutics is more attractive than Myomo.

Beam Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $14.3M, which are larger than Myomo quarterly revenues of $9.2M. Beam Therapeutics's net income of -$96.7M is lower than Myomo's net income of -$966.4K. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 6.80x versus 8.94x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -677.47% compared to Beam Therapeutics's net margin of -17.98%. Beam Therapeutics's return on equity of -16.62% beat Xtant Medical Holdings's return on equity of -35.98%.

Beam Therapeutics has a consensus price target of --, signalling upside risk potential of 69.42%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than Beam Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Beam Therapeutics.

Beam Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $14.3M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Beam Therapeutics's net income of -$96.7M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 6.80x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.